These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 24145678)

  • 41. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program.
    Gasche C; Ahmad T; Tulassay Z; Baumgart DC; Bokemeyer B; Büning C; Howaldt S; Stallmach A;
    Inflamm Bowel Dis; 2015 Mar; 21(3):579-88. PubMed ID: 25545376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical significance of C-reactive protein levels in predicting responsiveness to iron therapy in patients with inflammatory bowel disease and iron deficiency anemia.
    Iqbal T; Stein J; Sharma N; Kulnigg-Dabsch S; Vel S; Gasche C
    Dig Dis Sci; 2015 May; 60(5):1375-81. PubMed ID: 25501922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Iron (III) isomaltoside 1000.
    Mace TA; Syed A; Bhandari S
    Expert Rev Hematol; 2013 Jun; 6(3):239-46. PubMed ID: 23782077
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of iron isomaltoside ferumoxytol with iron sucrose for iron deficiency anemia: a meta-analysis of randomized controlled trials.
    Shi L; Zhao Y; Rao A
    Afr Health Sci; 2023 Sep; 23(3):205-212. PubMed ID: 38357109
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M; Font R; García C; Muñoz-Cortés M; Cabré C; Jariod M; Romeu M; Giralt M; Martinez-Vea A
    Clin Nephrol; 2014 Jun; 81(6):419-26. PubMed ID: 24691014
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial).
    Johansson PI; Rasmussen AS; Thomsen LL
    Vox Sang; 2015 Oct; 109(3):257-66. PubMed ID: 25900643
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized Open-Label Phase 1 Study of the Pharmacokinetics of Ferric Maltol in Inflammatory Bowel Disease Patients with Iron Deficiency.
    Bokemeyer B; Krummenerl A; Maaser C; Howaldt S; Mroß M; Mallard N
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):229-238. PubMed ID: 27101422
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
    Kulnigg S; Stoinov S; Simanenkov V; Dudar LV; Karnafel W; Garcia LC; Sambuelli AM; D'Haens G; Gasche C
    Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
    Womack R; Berru F; Panwar B; Gutiérrez OM
    Clin J Am Soc Nephrol; 2020 Sep; 15(9):1251-1258. PubMed ID: 32694162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous ferric derisomaltose versus oral iron for persistent iron deficient pregnant women: a randomised controlled trial.
    Hansen R; Sommer VM; Pinborg A; Krebs L; Thomsen LL; Moos T; Holm C
    Arch Gynecol Obstet; 2023 Oct; 308(4):1165-1173. PubMed ID: 36107229
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Feasibility of Intravenous Iron Isomaltoside to Improve Anemia and Quality of Life During Palliative Chemotherapy for Esophagogastric Adenocarcinoma.
    Ng O; Keeler B; Simpson JA; Madhusudan S; Brookes M; Acheson A
    Nutr Cancer; 2018 Oct; 70(7):1106-1117. PubMed ID: 30198775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT
    Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Perioperative changes in haemoglobin and ferritin concentrations from preoperative intravenous iron isomaltoside for iron deficiency anaemia in patients with colorectal cancer: A pilot randomised controlled trial.
    Fung PLP; Lau VNM; Ng FF; Leung WW; Mak TWC; Lee A
    PLoS One; 2022; 17(6):e0270640. PubMed ID: 35771891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy.
    Henry DH; Dahl NV; Auerbach M; Tchekmedyian S; Laufman LR
    Oncologist; 2007 Feb; 12(2):231-42. PubMed ID: 17296819
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial.
    Holm C; Thomsen LL; Norgaard A; Langhoff-Roos J
    Trials; 2015 Jan; 16():5. PubMed ID: 25588587
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.
    Shepshelovich D; Rozen-Zvi B; Avni T; Gafter U; Gafter-Gvili A
    Am J Kidney Dis; 2016 Nov; 68(5):677-690. PubMed ID: 27321965
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment with Noripurum EV
    Venturieri MO; Komati JTS; Lopes LHC; Sdepanian VL
    Scand J Gastroenterol; 2019 Feb; 54(2):198-204. PubMed ID: 30782036
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
    Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
    Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
    Khoury A; Pagan KA; Farland MZ
    Ann Pharmacother; 2021 Feb; 55(2):222-229. PubMed ID: 32633548
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.